[Optimizing the managment of patients with diabetes mellitus: selected clinical trials from the 2004 Congress of the American Diabetes Association].
The 64th scientific congress of the American Diabetes Association had a special session devoted to the presentation of the results from three clinical trials: 1) the first multicentre international trial of pancreatic islet transplantation according to the so-called Edmonton protocol with the primary endpoint of restoring insulin independence in type 1 diabetic patients; 2) three pivotal studies of 30 weeks testing both the efficacy and safety of exenatide (exendin-4), a new insulin secretagogue that is a long-acting analogue of glucagon-like peptide-1, in patients with type 2 diabetes treated with either metformin, or a sulfonylurea, or a metformin-sulfonylurea combination; and 3) the "Collaborative AtoRvastatin Diabetes Study" (CARDS), a placebo-controlled primary prevention trial of cardiovascular complications using atorvastatin 10 mg in 2 838 at risk patients with type 2 diabetes. The main results and conclusions of these trials are briefly presented as they open new perspectives in the management of patients with type 1 or type 2 diabetes mellitus.
Scheen
A J
AJ
Service de Diabétologie, Nutrition et Maladies métaboliques, Département de Médecine, CHU Sart Tilman, Liège.
Radermecker
R P
RP
Philips
J C
JC
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D002986:Clinical Trials as Topic; D048909:Diabetes Complications / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000628:therapy*; D000077270:Exenatide; D005934:Glucagon / Q000627:therapeutic use; D052216:Glucagon-Like Peptide 1; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D016381:Islets of Langerhans Transplantation; D010446:Peptide Fragments / Q000627:therapeutic use; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors / Q000627:therapeutic use; D011758:Pyrroles / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D010446:Peptide Fragments; D010455:Peptides; D011498:Protein Precursors; D011758:Pyrroles; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D000077270:Exenatide; D000069059:Atorvastatin